News and Trends 29 Aug 2022 Sanyou and KangaBio to collaborate on antibody drug development and innovation Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […] August 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Swedish researchers developing new treatment for chronic hepatitis B and D infections A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet in Sweden, have been published in the journal Gut. Chronic infections of the hepatitis B virus (HBV) and hepatitis […] August 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […] August 26, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Ordaōs raises $5M to accelerate drug design and discovery U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […] August 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 3T Biosciences launches with $40M financing 3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Scottish researchers can tap into new £300K fund Precision Medicine Scotland Innovation Centre (PMS-IC), the national center for accelerating the advancement and adoption of precision medicine, has launched a new fund to support Scottish researchers. The $300,000 ($355,000) fund, the first offered by PMS-IC, will support research ideas to support accurate diagnosis and/or treatment based on an individual’s unique biology. Funds of up […] August 25, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 New drug boosts options for rheumatoid arthritis treatment In its final phase III clinical trial, a new drug for treating rheumatoid arthritis has proved to be at least as effective as the current “gold standard” treatment for this autoimmune disease. This opens up new treatment options for affected patients. The results of the international multicentre study led by MedUni Vienna were recently published […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents. These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in […] August 25, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Hera Biotech bags $1.9M for endometriosis diagnostic test San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Study findings could lead to new anti-cancer drugs German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system. Many tumor cells mist themselves with a protective ‘perfume’ that disables the immune system. But a drug already approved for other purposes can apparently render this weapon harmless. This is the conclusion of a […] August 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Potential new treatment for angioimmunoblastic T-cell lymphoma? A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email